Withings, the French connected health device specialist founded in 2008 by Éric Carreel and Cédric Hutchings, has reached profitability for the first time in its 18-year history. The milestone, disclosed in its 2024 financial results, marks a long-awaited vindication for a company that survived a turbulent acquisition by Nokia in 2016 and a management buyback just two years later.

The firm reported full-year revenue of €100 million, a 47% jump compared to €68 million in 2023, and posted a net profit of €1.5 million. CEO Éric Carreel said in a statement: “This achievement demonstrates that our model—combining consumer-grade design with medical-grade accuracy and a recurring services layer—can be economically viable without sacrificing long-term R&D bets.” R&D spending remains high at roughly 30% of revenue, reflecting the company’s focus on clinical validation for its products.

Withings’ revival has been built on a series of critically acclaimed devices. The Body Scan connected scale, which measures segmental body composition, nerve activity, and cardiovascular health, has been a strong seller since its launch. The ScanWatch 2, a hybrid smartwatch with temperature tracking and sleep apnea detection, and the U-Scan, a urine analysis pod that sits in a toilet bowl, have bolstered the premium health-monitoring lineup. A subscription service, Withings+, provides in-depth health reports and coaching, contributing to a growing share of recurring revenue.

The path to profitability was anything but smooth. After early success with its first connected scale in 2009, Withings was bought by Nokia in 2016 for €170 million, only to see its innovation pace stall under the Finnish giant. Carreel repurchased the assets in 2018 for a fraction of the price, leading a restructuring that refocused the company on medical-grade consumer devices. The COVID-19 pandemic delayed some product launches, but the following years saw a steady climb in sales as health awareness surged.

Looking ahead, Carreel aims to expand Withings’ footprint in the United States and Asia, where partnerships with healthcare providers are budding. The company also plans to deepen its ecosystem of devices and services, leveraging artificial intelligence to turn raw biometric data into actionable health insights. While profitability is modest, the achievement signals that Withings has finally found a sustainable formula at the intersection of consumer tech and regulated health data.

L’article 18 ans plus tard, Withings devient rentable est apparu en premier sur Maddyness - Le média pour comprendre l'économie de demain.